Search for: "Ives, A. v. Ives, K."
Results 141 - 160
of 625
Sorted by Relevance
|
Sort by Date
28 Jun 2010, 11:31 am
SCHEDULE V examples include but are not limited to: Ephedrine, except as provided in division (K) of section 3719.44 of the Revised Code, and various other drugs in compound form. [read post]
22 Jan 2007, 9:53 am
Kenneth Thien, Karen K. [read post]
1 May 2018, 4:14 am
Sladkus, an attorney, brings this defamation action against Melanie Englese a/k/a Melanie Sisskind, his former client. [read post]
4 Mar 2013, 7:58 am
Happily Herr K was able to announce to his judicial inquisitor that someone manning security on the way into court had indeed addressed him as Mr Ka-link, to the general amusement of those in court -- both on the bench and before it. [read post]
1 Jan 2014, 5:01 pm
330 x 103 and a Mw/Mn of 20-35,and comprising(v) a low molecular weight (LMW) ethylene homopolymer fraction and a high molecular weight (HMW) ethylene copolymer fraction in a weight ratio of the LMW fraction to the HMW fraction of (35-55) : (65-45)(vi) said HMW ethylene copolymer fraction having a lower molecular weight limit of 3500.[2.2] The contested decision nor the parties on appeal addressed the question whether the present patent specification disclosed a technical concept fit for… [read post]
17 Aug 2015, 6:57 am
Between July 12 and July 16, 2013, FanFest operated in the Jacob K. [read post]
4 Feb 2014, 8:53 am
IV. [read post]
22 Oct 2024, 2:35 pm
Exporting Chinese Digital AuthoritarianismMartin K. [read post]
6 Sep 2012, 5:25 pm
District Court for the District of Columbia dealt a blow to K-V Pharmaceutical Company’s (“KV’s”) efforts to “restore” orphan drug exclusivity for the pre-term birth drug MAKENA (hydroxyprogesterone caproate) Injection, 250 mg/mL, by granting FDA’s Motion to Dismiss a case filed by KV back in early July. [read post]
16 Dec 2024, 7:58 pm
The guidance also clarifies the criteria for re-recognition of third party 510(k) review organizations and the suspension or withdrawal of recognition and discusses how FDA will audit the Third Party 510(k) Review Program as part of ongoing audit plans under the Quality Management and Organizational Excellence (QMOE) Program which are all Medical Device User Fee Amendments (MDUFA) IV and V commitments. [read post]
29 Jan 2020, 1:18 am
” 750 ILCS 5/501(b); see also Wilson v. [read post]
10 Apr 2017, 12:18 pm
§ 1125(a) Count III: Unfair Competition Count IV: Trademark Dilution under 15 U.S.C. [read post]
11 Sep 2008, 1:31 pm
In LaSalle Bank NA v. [read post]
10 Apr 2017, 12:18 pm
§ 1125(a) Count III: Unfair Competition Count IV: Trademark Dilution under 15 U.S.C. [read post]
22 Nov 2007, 3:49 pm
Here are the rules for Superior Court of New Hampshire 111 K. [read post]
5 Mar 2023, 9:01 pm
The introductory language to Item 402(v) provides that PVP disclosure must be included in any “proxy or information statement” for which the SEC requires executive compensation disclosure pursuant to Item 402 of Regulation S-K. [read post]
9 Sep 2013, 9:23 am
He went on to defend his hypothesis based on text of Section 2(m) and 51(b)(iv). [read post]
16 Mar 2011, 6:10 am
In Alcorn v. [read post]
9 Oct 2011, 5:01 pm
Claim 1 of all those requests, compared to claim 1 as granted, was restricted by the use of an additional ingredient (v) defined to be a single non-volatile emollient or a mixture of emollients selected from fatty acids, fatty alcohol esters, slightly water-soluble ethers and alcohols, hydrocarbons, water-insoluble ethers, mineral oils and polyorganosiloxanes. [read post]
8 Mar 2014, 3:01 pm
Amzak Capital Mgmt. v. [read post]
